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Table 1. Risk factor analysis of transplant outcomes in 72
patients with T-ALL treated with haplo-identical/mismatched
HSCT
Risk factor LFS Relapse NRM
HLA non-identical locus
1-2 n 5 31 52% 24% 17%
3 n 5 41 39% 21% 35%
p 0.15 0.77 0.068
Gender
Male n 5 55 51% 21% 21%
Female n 5 17 16% 27% 53%
p 0.040 0.61 0.08
Diagnostic WBC
Less than 100 n 5 57 48% 23% 23%
100 or more n 5 15 27% 22% 46%
p 0.27 0.99 0.22
CNS involvement
Yes n 5 12 58% 33% 8%
No n 5 60 37% 21% 33%
p 0.44 0.29 0.09
Tumor mass
Yes n 5 38 37% 33% 32%
No n 5 34 52% 10% 24%
p 0.14 0.02 0.64
Time from chemo to CR1
#30d n 5 40 48% 18% 28%
>30d n 5 32 38% 29% 26%
p 0.12 0.19 0.70
Disease status before HSCT
CR1 n 5 56 58% 18% 16%
Non-CR1 n 5 16 12% 37% 50%
p 0.001 0.08 0.04
Disease duration before HSCT
#7 months n 5 38 50% 23% 23%
>7 monts n 5 34 37% 22% 33%
p 0.42 0.96 0.39
Age
< 35 years n 5 59 42% 26% 24%
$35 years n 5 13 47% 8% 43%
p 0.87 0.17 0.12
Median MNCs, x108/kg
#7.5 n 5 36 40% 21% 34%
>7.5 n 5 36 50% 24% 22%
p 0.61 0.58 0.15
Poster Session II S343irradiation (PPTBI) and evaluate these variables as predictors of
post-SCT survival.
Design & Methods: The study employed a retrospective, descrip-
tive design with convenience sampling of patients treated with
PPTBI at the University of Rochester Medical Center 2001-2010;
De-identified data were extracted from the medical records on IRB
approved protocol. All statistical analyses were performed utilizing
SPSS 19.0.
Results: In the final sample size of 103 patients, mean recipient age
was 56.6 (SD9.9; range 20-70). The sample was 34% female and 66%
male. Disease type included ALL (1.9%), AML (33%), CLL
(20.4%), CML (4.9%), HL (4.9%), MDS (8.7%), MM (1.9%),
MPN (6.8%), NHL (16.5%), and PCD (1%). Disease status in-
cluded: 1st response (30.1%), 2nd response (38.8%), refractory
(16.5%), untreated (4.9%), and other (9.7%). Related (43.7%) and
unrelated (56.3%) donors were utilized. HCT-CI scores were cate-
gorized into low (10.7%), intermediate (31.1%), and high (58.3%)
risk. Median survival was 298 days (SD825.4; range10-2881);
38.8% were alive at study endpoint. Bivariate analyses (alpha 5
.05) revealed a significant association between survival and age, dis-
ease type, disease status, and HCT-CI category (all p\.001), but not
donor relatedness. Survival was regressed on the explanatory vari-
ables with stepwise addition of HCT-CI which remained the only
significant predictor of survival in this sample (c2 5 11.35, df 2,
p 5 .003). Subjects in low (HR .31,95% CI:.101,.961, p 5 .042)
and intermediate (HR .41, 95%CI:.214,.775, p 5 .006) groups by
HCT-CI had significantly better survival compared to those in the
high risk group.
Conclusion:Our findings contribute to the validity and reliability of
HCT-CI as a predictor of survival after reduced intensity SCT in all
types of hematologic malignancies. We conclude that the HCT-CI
assessment should routinely be performed to facilitate risk estima-
tion and decision-making with patients who are considering SCT
and further prospective studies are needed to confirm these
findings.
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Mismatched related donor HSCT for severe aplastic anemia
(SAA) presents challenges, mainly associated with graft failure and
GVHD. Non-engraftment and graft rejection after allo-HSCT for
SAA has been strongly associated with higher degrees of histoincom-
patibility and allosensitization to histocompatibility antigens due to
previous blood product transfusions. Earlier reports have suggested
that the greater the HLA disparity, the poorer the overall survival
(OS), less than 20% survival for two or more loci-mismatched recip-
ients. Recently, progress has been made in haploidentical HSCT,
which is now used to perform haploidentical non-T-cell-depleted
HSCT for patients with hematological malignancies, it is not known
whether the similar procedure could be used for patients with SAA.
We report the results of 19 consecutive SAA/VSAA patients who re-
ceived haploidentical-HSCT. All cases failed to previous therapy and
were heavily transfused prior to transplantation. Among these, 9
cases had 3 loci mismatches, 9 cases had 2 loci mismatches, and 1
case had 1 locus mismatch. All patients were treated with a regimen
which consisted of the following: busulfan (6.4mg/kg i.v. in 8 doses);
cyclophosphamide (200mg/kg, i.v. in 4 doses); and ATG (10mg/kg
i.v.,rabbit, of the Sangstat product or 80mg/kg i.v.,porcine,the Bio-
product, Wuhan, in 4 doses).All recipients received CsA, mycophe-
nolate mofetil, and short-term MTX for GVHD prophylaxis. The
source of stem cell grafts was a combination of G-CSF-primed
BM and G-CSF-mobilized peripheral blood stem cells. All patients
achieved 100%donormyeloid engraftment; themedian time formy-
eloid engraftment was 12 days (ranging from 10-29 days) and 18 days
(ranging from 8-180 days) for platelets, with a cumulative platelet en-
graftment incidence of 84.21 6 10.53%. Two patients (10.5%) suf-
fered late graft rejection. The cumulative incidence was 42.1 6
11.3% for grade II-IV acute GVHD (aGVHD) and 21.1 6 9.4%for grade III-IV aGVHD. The cumulative incidence was 56.2 6
12.4% for chronic GVHD (cGVHD) and 12.56 8.3% for extensive
cGVHD.Of 13 surviving patients with amedian 746 d (90-1970) fol-
low-up, OS was 64.66 12.4%. The independent high risk factors to
OS are grade II-IV aGVHD and mononuclear cells (MNC) infused
\8.84x108/kg. These limited data suggest that HLA-mismatched/
haploidentical HSCT for SAA patients without an HLA-identical
sibling donor may be feasible. Properly controlled trials will be
needed to confirm this conclusion.
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The outcome of T-cell acute lymphoblastic leukemia (T-ALL)
is poorly understood. Allogeneic hematopoietic stem cell
